ANSM

ANSM
Name	Agence Nationale de Sécurité du Médicament et des Produits de Santé
Formed	2012
Preceding1	Agence française de sécurité sanitaire des produits de santé
Jurisdiction	France
Headquarters	Paris
Chief1 name	(Director)
Parent agency	Ministry of Solidarity and Health

ANSM

The Agence Nationale de Sécurité du Médicament et des Produits de Santé is the French national authority responsible for the evaluation, supervision, and safety monitoring of medicinal products and medical devices. It operates at the intersection of regulatory frameworks such as the European Medicines Agency, national statutes including the Public Health Code, and international standards from organizations like the World Health Organization, coordinating with institutions such as the Institut Pasteur and the Centre national de la recherche scientifique. ANSM’s remit touches pharmaceutical industry stakeholders including Sanofi, Pfizer, and Roche, academic centers such as Université Paris-Saclay, and clinical institutions like Assistance Publique–Hôpitaux de Paris.

History

ANSM was created in 2012 as a successor to the Agence française de sécurité sanitaire des produits de santé following reforms prompted by public health crises and legislative changes in the wake of incidents involving Mediator and other pharmacovigilance failures. Its establishment intersected with initiatives from the French Parliament, oversight by the Conseil d’État, and policy responses advocated by figures associated with public inquiries and commissions. Since inception, ANSM has adapted to EU regulatory developments led by the European Commission and coordination mechanisms linked to the European Medicines Agency and national competent authorities across Germany, Italy, Spain, and the United Kingdom. Its timeline includes regulatory responses to outbreaks and therapeutic innovations like vaccines developed by Moderna, AstraZeneca, and BioNTech, as well as oversight of medical devices implicated in controversies involving Johnson & Johnson and Philips Respironics.

Organization and Governance

ANSM’s governance structure situates a board and executive leadership within oversight from the Ministry of Solidarity and Health and interactions with the Court of Auditors on budgetary matters. Internal directorates oversee scientific assessment, pharmacovigilance, inspection, and legal affairs; these work with expert committees and external advisers drawn from institutions such as Institut Pasteur, INSERM, Université de Bordeaux, and Université de Strasbourg. Governance includes ethics and transparency obligations responding to scrutiny from parliamentary committees and nongovernmental organizations like Transparency International and Médecins Sans Frontières. ANSM maintains administrative links with EU agencies including the European Medicines Agency and collaborates with international partners such as the World Health Organization and the Organisation for Economic Co-operation and Development.

Roles and Responsibilities

ANSM’s core responsibilities encompass marketing authorization oversight, surveillance of adverse reactions, risk communication, and enforcement of quality standards for manufacturers like Sanofi, Novartis, and GlaxoSmithKline. It assesses clinical trial applications involving sponsors such as CNRS laboratories and private companies, inspects manufacturing sites including those owned by Pfizer and Merck, and certifies conformity of medical devices distributed by companies like Stryker and Medtronic. The agency issues safety advisories affecting prescribers in hospitals such as Hôpital Cochin and Hôpital Necker–Enfants Malades, and informs professional orders including the Ordre des Médecins and Ordre des Pharmaciens. ANSM also participates in emergency responses alongside agencies such as Santé Publique France and coordinates with European counterparts during cross-border safety issues exemplified by joint actions with Germany’s Bundesinstitut für Arzneimittel und Medizinprodukte.

Regulation and Approval Processes

ANSM evaluates marketing authorization applications under national procedures and contributes to centralized and decentralized dossiers within the European regulatory network led by the European Medicines Agency. Its scientific assessment engages experts from INSERM, CNRS, and university hospitals, applying guidance influenced by International Council for Harmonisation standards and legal frameworks derived from the French Public Health Code and rulings by the Conseil d’État. The agency coordinates inspections invoking standards from ISO and Good Manufacturing Practice frameworks, inspects sites operated by multinational firms such as AstraZeneca and Eli Lilly, and adjudicates labelling, packaging, and risk management plans. For medical devices, ANSM applies conformity assessment procedures that interface with notified bodies like Bureau Véritas and TÜV SÜD and regulatory mechanisms emerging from the EU Medical Device Regulation.

Pharmacovigilance and Safety Monitoring

ANSM operates a national pharmacovigilance system receiving reports from healthcare professionals in hospitals such as Hôpital Saint-Louis and community pharmacists affiliated with national syndicats, evaluating signals in coordination with the European Medicines Agency and WHO pharmacovigilance programmes. It maintains databases to analyze adverse events associated with vaccines from companies like Pfizer–BioNTech, Moderna, and AstraZeneca, and with products manufactured by companies including Bayer and AbbVie. ANSM issues safety warnings, mandates label changes, and can require risk minimization measures or market withdrawals following procedures comparable to those used by the Medicines and Healthcare products Regulatory Agency and the U.S. Food and Drug Administration. It also oversees post-authorisation safety studies conducted by academic groups and industry sponsors, and collaborates with pharmacovigilance centres hosted by universities such as Université de Lyon.

Controversies and Criticisms

ANSM has faced criticism related to responses to the Mediator scandal antecedent, the pace of action during safety signals involving medical devices such as hip implants produced by DePuy, and transparency debates similar to controversies encountered by the European Medicines Agency and national authorities in Germany and the United Kingdom. Parliamentary inquiries and reports from institutions including the Cour des comptes and patient advocacy groups have challenged aspects of conflict-of-interest management, communication strategy during vaccine roll-outs involving AstraZeneca and Janssen, and the handling of clinical trial approvals for high-profile therapies. NGOs such as Médecins du Monde and regulatory scholars have called for reforms mirroring proposals debated in the French Parliament and at the European Commission level to strengthen independence and public trust, while industry associations have highlighted the need for regulatory predictability to support innovation from companies like Sanofi and Roche.

Category:Medical and health organizations based in France